SGLT2 inhibitors for kidney and heart disease Normally used as a glucose-lowering agent in the treatment of type 2 diabetes, SGLT2 inhibitors have been found to have beneficial effects in patients with heart failure and kidney disease.
New Alzheimer’s medication found to slow cognitive decline The drug may be available as early as 2023, but there are still hurdles to cross, write Bernadette McGuinness and Elizabeth Coulthard.
Could ‘nurse navigators’ help the severely mentally ill? People with serious mental illness are dying much earlier than average from entirely preventable diseases, a situation a new policy aims to improve.
New PIP QI dataset provides ‘snapshot’ of general practice More than 5600 general practices took part in the program – but given the current pandemic environment, how much insight is it providing?
What to know about heart attack and stroke risks after COVID-19 A new study warns that COVID-19’s impact on blood vessels could drive a new pandemic of cardiovascular disease.
Outcomes from the new CVD risk calculator depend on integration The benefits of updated guidelines will be missed if implementation issues are not urgently addressed, a GP and CVD researcher believe.
Chronic kidney disease: A patient perspective on navigating a new diagnosis GP Dr Kate Annear speaks with Dan and Jody, who have a lived experience with chronic kidney disease. They discuss helpful resources, as well as advice for health professionals looking to make the patient journey easier.
Medical software data provides fresh insight into general practice A new report containing de-identified 2020–21 data from around 10% of Australian GPs and patients has been released.
Healthcare services for heart failure patients underutilised: Research A new study suggests half a million Australians with heart failure are missing out on optimal care, presenting an ‘opportunity’ for GPs.
How self-targeted immune attacks may lurk behind long COVID Researchers are closing in on the link between antiviral immunity and chronic autoimmune disease, writes immunologist Matthew Woodruff.